


## Sugammadex sodium

<b>Cat. No.:</b>	HY-B0079
<b>CAS No.:</b>	343306-79-6
<b>Molecular Formula:</b>	$C_{72}H_{104}Na_8O_{48}S_8$
<b>Molecular Weight:</b>	2178.01
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (45.91 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		0.4591 mL	2.2957 mL	4.5913 mL
		<b>5 mM</b>		0.0918 mL	0.4591 mL	0.9183 mL
<b>10 mM</b>		0.0459 mL	0.2296 mL	0.4591 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (45.91 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Sugammadex sodium is a synthetic $\gamma$ -cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury <sup>[1][2]</sup> .
<b>In Vivo</b>	Sugammadex (100 mg/kg, IV, once) has a nephroprotective effect when given at the beginning of reperfusion after one hour of ischemic condition on rats <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

<b>Animal Administration</b> <sup>[1]</sup>	Female rhesus monkeys with a body weight of 5.2-7.1 kg are sedated with 10 mg/kg ketamine intramuscularly. Two intravenous lines are placed: one for anesthetization, including rocuronium, the other for test drug administration. This is followed by intravenous injection of 25 mg/kg pentobarbitone sodium and a subsequent continuous infusion of 5-10
---	--

mg/kg/h. The monkeys are intubated endotracheally, and the lungs are ventilated with a mixture of oxygen and nitrous oxide (volume ratio of 2:3). Four animals are each studied on three different occasions. The occasions differed by the administration of either saline or a low (1.0 mg/kg) or high (2.5 mg/kg) dose of sugammadex. Between the experiments, the monkeys recover for at least 6 weeks. Heart rate and oxygen saturation are determined at the ear with a pulse oximeter. Blood pressure is determined with a cuff placed around the tail. Body temperature is measured by a rectal probe and kept at 37°C-38°C.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Tercan M, Yilmaz Inal F, Seneldir H, Kocoglu H. Nephroprotective Efficacy of Sugammadex in Ischemia-Reperfusion Injury: An Experimental Study in a Rat Model. *Cureus*. 2021 Jun 17;13(6):e15726.
- [2]. de Boer HD, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. *Anesthesiology*. 2006 Apr;104(4):718-23.
- [3]. de Boer HD, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. *Br J Anaesth*. 2006 Apr;96(4):473-9. Epub 2006 Feb 7.
- [4]. de Boer HD, et al. Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. *Br J Anaesth*. 2006 Nov;97(5):681-6. Epub 2006 Oct 3.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA